I. Introduction American Journal of Kidney Diseases   American Journal of Kidney Diseases  Volume 41, Pages S11-S21 (April 2003) DOI: 10.1016/S0272-6386(03)00119-7

Fig 1 The evolution of National Kidney Foundation guidelines for the management of dyslipidemias in patients with chronic kidney disease. To convert serum creatinine from mg/dL to mmol/L, multiply by 88.4. Abbreviations: Cr, serum creatinine; ESRD, end-stage renal disease; NCEP, National Cholesterol Education Program; CVD, cardiovascular disease; GFR, glomerular filtration rate; CKD, chronic kidney disease; K/DOQI, Kidney Disease Outcomes Quality Initiative. American Journal of Kidney Diseases 2003 41, S11-S21DOI: (10.1016/S0272-6386(03)00119-7)

Fig 2 Ages covered by the current guidelines, and those covered by previous guidelines developed for use in the general population. American Journal of Kidney Diseases 2003 41, S11-S21DOI: (10.1016/S0272-6386(03)00119-7)

Fig 3 The chain of logic for evidence supporting the treatment of low-density lipoprotein cholesterol in patients with chronic kidney disease. See text for details. Abbreviations: LDL, low-density lipoprotein; CHD, coronary heart disease; CKD, chronic kidney disease. American Journal of Kidney Diseases 2003 41, S11-S21DOI: (10.1016/S0272-6386(03)00119-7)

Fig 4 The relative coronary heart disease risk reduction in subgroups of patients from major lipid-lowering trials in the general population. The bars indicate the mean relative risk reduction (compared to a reference level of 0% reduction), with a higher number indicating a proportionally greater reduction in risk. The error bars represent 95% confidence intervals. There were at least 20,000 patients in each category (divided between “no” and “yes”). The only category where the risk reduction was statistically different was for baseline LDL (lower panel), where patients with a higher baseline LDL had a greater reduction in risk, although patients with lower and higher baseline cholesterol had significant risk reductions. Data are from Table II.2–3 of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (www.nhlbi.nih.gov/guidelines/cholesterol/index.htm). American Journal of Kidney Diseases 2003 41, S11-S21DOI: (10.1016/S0272-6386(03)00119-7)